ViiV’s Cabenuva Proves Superior in HIV Adherence Study, Setting New Standard for Treatment
Event summary
- ViiV Healthcare’s Cabenuva (cabotegravir + rilpivirine) demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with adherence challenges, per 48-week LATITUDE trial data published in NEJM.
- The trial, sponsored by NIAID and conducted by ACTG, showed a 48% reduction in regimen failure risk for Cabenuva versus daily oral therapy.
- Cabenuva’s success could validate long-acting injectables as a preferred treatment option for HIV patients with adherence challenges.
- ViiV is conducting the CROWN study to evaluate Cabenuva in individuals with detectable virus, expanding its potential patient base.
The big picture
ViiV Healthcare’s Cabenuva represents a significant advancement in HIV treatment, particularly for patients struggling with daily oral therapy adherence. The LATITUDE trial results reinforce the potential of long-acting injectables to improve treatment outcomes and reduce the burden of chronic medication management. This success could accelerate the shift toward injectable therapies in HIV care, positioning ViiV as a leader in this evolving treatment landscape.
What we're watching
- Market Adoption
- Whether Cabenuva can gain broader acceptance among HIV patients and healthcare providers, particularly those with adherence challenges.
- Regulatory Approval
- The pace at which regulatory agencies may expand Cabenuva’s indications based on the LATITUDE and CROWN trial results.
- Competitive Dynamics
- How ViiV’s success with Cabenuva will impact competitors developing long-acting HIV treatments.
Related topics